OTCMKTS:SSDOY

Shiseido Competitors

$73.64
+0.76 (+1.04 %)
(As of 05/7/2021 12:00 AM ET)
Add
Compare
Today's Range
$73.46
$73.80
50-Day Range
$66.92
$75.63
52-Week Range
$51.10
$79.55
Volume7,511 shs
Average Volume19,000 shs
Market Capitalization$29.41 billion
P/E RatioN/A
Dividend Yield0.37%
Beta0.33

Competitors

Shiseido (OTCMKTS:SSDOY) Vs. GSK, CSLLY, ZTS, BAYRY, VRTX, and TAK

Should you be buying SSDOY stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Shiseido, including GlaxoSmithKline (GSK), CSL (CSLLY), Zoetis (ZTS), Bayer Aktiengesellschaft (BAYRY), Vertex Pharmaceuticals (VRTX), and Takeda Pharmaceutical (TAK).

Shiseido (OTCMKTS:SSDOY) and GlaxoSmithKline (NYSE:GSK) are both large-cap consumer staples companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, risk, analyst recommendations, profitability, earnings, institutional ownership and valuation.

Analyst Recommendations

This is a summary of recent ratings and target prices for Shiseido and GlaxoSmithKline, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Shiseido22202.00
GlaxoSmithKline34602.23

Profitability

This table compares Shiseido and GlaxoSmithKline's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Shiseido-1.33%0.95%0.40%
GlaxoSmithKline18.50%29.60%7.11%

Volatility & Risk

Shiseido has a beta of 0.33, indicating that its share price is 67% less volatile than the S&P 500. Comparatively, GlaxoSmithKline has a beta of 0.67, indicating that its share price is 33% less volatile than the S&P 500.

Valuation & Earnings

This table compares Shiseido and GlaxoSmithKline's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Shiseido$10.38 billion2.83$676.77 million$1.7242.81
GlaxoSmithKline$43.10 billion2.40$5.93 billion$3.1712.10

GlaxoSmithKline has higher revenue and earnings than Shiseido. GlaxoSmithKline is trading at a lower price-to-earnings ratio than Shiseido, indicating that it is currently the more affordable of the two stocks.

Dividends

Shiseido pays an annual dividend of $0.27 per share and has a dividend yield of 0.4%. GlaxoSmithKline pays an annual dividend of $2.52 per share and has a dividend yield of 6.6%. Shiseido pays out 15.7% of its earnings in the form of a dividend. GlaxoSmithKline pays out 79.5% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future.

Institutional & Insider Ownership

0.1% of Shiseido shares are held by institutional investors. Comparatively, 11.8% of GlaxoSmithKline shares are held by institutional investors. 10.0% of GlaxoSmithKline shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

GlaxoSmithKline beats Shiseido on 13 of the 15 factors compared between the two stocks.

Shiseido (OTCMKTS:SSDOY) and CSL (OTCMKTS:CSLLY) are both large-cap consumer staples companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, risk, analyst recommendations, profitability, earnings, institutional ownership and valuation.

Analyst Recommendations

This is a summary of recent ratings and target prices for Shiseido and CSL, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Shiseido22202.00
CSL02302.60

Profitability

This table compares Shiseido and CSL's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Shiseido-1.33%0.95%0.40%
CSLN/AN/AN/A

Volatility & Risk

Shiseido has a beta of 0.33, indicating that its share price is 67% less volatile than the S&P 500. Comparatively, CSL has a beta of 0.59, indicating that its share price is 41% less volatile than the S&P 500.

Valuation & Earnings

This table compares Shiseido and CSL's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Shiseido$10.38 billion2.83$676.77 million$1.7242.81
CSL$9.15 billion10.74$2.10 billion$2.3146.75

CSL has lower revenue, but higher earnings than Shiseido. Shiseido is trading at a lower price-to-earnings ratio than CSL, indicating that it is currently the more affordable of the two stocks.

Dividends

Shiseido pays an annual dividend of $0.27 per share and has a dividend yield of 0.4%. CSL pays an annual dividend of $0.94 per share and has a dividend yield of 0.9%. Shiseido pays out 15.7% of its earnings in the form of a dividend. CSL pays out 40.7% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

Institutional & Insider Ownership

0.1% of Shiseido shares are held by institutional investors. Comparatively, 0.2% of CSL shares are held by institutional investors. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

CSL beats Shiseido on 10 of the 14 factors compared between the two stocks.

Shiseido (OTCMKTS:SSDOY) and Zoetis (NYSE:ZTS) are both large-cap consumer staples companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, risk, analyst recommendations, profitability, earnings, institutional ownership and valuation.

Volatility & Risk

Shiseido has a beta of 0.33, indicating that its share price is 67% less volatile than the S&P 500. Comparatively, Zoetis has a beta of 0.71, indicating that its share price is 29% less volatile than the S&P 500.

Dividends

Shiseido pays an annual dividend of $0.27 per share and has a dividend yield of 0.4%. Zoetis pays an annual dividend of $1.00 per share and has a dividend yield of 0.6%. Shiseido pays out 15.7% of its earnings in the form of a dividend. Zoetis pays out 27.5% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Zoetis has raised its dividend for 1 consecutive years. Zoetis is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Institutional & Insider Ownership

0.1% of Shiseido shares are held by institutional investors. Comparatively, 92.5% of Zoetis shares are held by institutional investors. 0.2% of Zoetis shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Shiseido and Zoetis' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Shiseido-1.33%0.95%0.40%
Zoetis25.50%63.89%14.99%

Analyst Recommendations

This is a summary of recent ratings and target prices for Shiseido and Zoetis, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Shiseido22202.00
Zoetis05902.64

Zoetis has a consensus price target of $178.1818, indicating a potential upside of 3.87%. Given Zoetis' stronger consensus rating and higher possible upside, analysts clearly believe Zoetis is more favorable than Shiseido.

Valuation & Earnings

This table compares Shiseido and Zoetis' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Shiseido$10.38 billion2.83$676.77 million$1.7242.81
Zoetis$6.26 billion13.02$1.50 billion$3.6447.13

Zoetis has lower revenue, but higher earnings than Shiseido. Shiseido is trading at a lower price-to-earnings ratio than Zoetis, indicating that it is currently the more affordable of the two stocks.

Summary

Zoetis beats Shiseido on 15 of the 17 factors compared between the two stocks.

Shiseido (OTCMKTS:SSDOY) and Bayer Aktiengesellschaft (OTCMKTS:BAYRY) are both large-cap consumer staples companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, dividends, earnings, valuation, institutional ownership and risk.

Volatility and Risk

Shiseido has a beta of 0.33, meaning that its stock price is 67% less volatile than the S&P 500. Comparatively, Bayer Aktiengesellschaft has a beta of 1.34, meaning that its stock price is 34% more volatile than the S&P 500.

Dividends

Shiseido pays an annual dividend of $0.27 per share and has a dividend yield of 0.4%. Bayer Aktiengesellschaft pays an annual dividend of $0.41 per share and has a dividend yield of 2.5%. Shiseido pays out 15.7% of its earnings in the form of a dividend. Bayer Aktiengesellschaft pays out 23.2% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

Institutional & Insider Ownership

0.1% of Shiseido shares are owned by institutional investors. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares Shiseido and Bayer Aktiengesellschaft's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Shiseido-1.33%0.95%0.40%
Bayer Aktiengesellschaft-22.32%14.23%5.01%

Analyst Ratings

This is a summary of recent ratings and recommmendations for Shiseido and Bayer Aktiengesellschaft, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Shiseido22202.00
Bayer Aktiengesellschaft18702.38

Valuation and Earnings

This table compares Shiseido and Bayer Aktiengesellschaft's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Shiseido$10.38 billion2.83$676.77 million$1.7242.81
Bayer Aktiengesellschaft$48.23 billion1.27$4.58 billion$1.779.31

Bayer Aktiengesellschaft has higher revenue and earnings than Shiseido. Bayer Aktiengesellschaft is trading at a lower price-to-earnings ratio than Shiseido, indicating that it is currently the more affordable of the two stocks.

Summary

Bayer Aktiengesellschaft beats Shiseido on 10 of the 14 factors compared between the two stocks.

Shiseido (OTCMKTS:SSDOY) and Vertex Pharmaceuticals (NASDAQ:VRTX) are both large-cap consumer staples companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, dividends, earnings, valuation, institutional ownership and risk.

Volatility and Risk

Shiseido has a beta of 0.33, suggesting that its share price is 67% less volatile than the S&P 500. Comparatively, Vertex Pharmaceuticals has a beta of 0.79, suggesting that its share price is 21% less volatile than the S&P 500.

Insider & Institutional Ownership

0.1% of Shiseido shares are owned by institutional investors. Comparatively, 92.2% of Vertex Pharmaceuticals shares are owned by institutional investors. 0.7% of Vertex Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Shiseido and Vertex Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Shiseido-1.33%0.95%0.40%
Vertex Pharmaceuticals38.51%28.55%20.68%

Analyst Ratings

This is a summary of recent ratings and recommmendations for Shiseido and Vertex Pharmaceuticals, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Shiseido22202.00
Vertex Pharmaceuticals041612.86

Vertex Pharmaceuticals has a consensus price target of $293.4737, indicating a potential upside of 36.49%. Given Vertex Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Vertex Pharmaceuticals is more favorable than Shiseido.

Earnings & Valuation

This table compares Shiseido and Vertex Pharmaceuticals' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Shiseido$10.38 billion2.83$676.77 million$1.7242.81
Vertex Pharmaceuticals$4.16 billion13.37$1.18 billion$4.2950.12

Vertex Pharmaceuticals has lower revenue, but higher earnings than Shiseido. Shiseido is trading at a lower price-to-earnings ratio than Vertex Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Summary

Vertex Pharmaceuticals beats Shiseido on 14 of the 15 factors compared between the two stocks.

Shiseido (OTCMKTS:SSDOY) and Takeda Pharmaceutical (NYSE:TAK) are both large-cap consumer staples companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, dividends, earnings, valuation, institutional ownership and risk.

Volatility and Risk

Shiseido has a beta of 0.33, meaning that its stock price is 67% less volatile than the S&P 500. Comparatively, Takeda Pharmaceutical has a beta of 1.01, meaning that its stock price is 1% more volatile than the S&P 500.

Profitability

This table compares Shiseido and Takeda Pharmaceutical's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Shiseido-1.33%0.95%0.40%
Takeda Pharmaceutical3.04%13.46%5.02%

Institutional & Insider Ownership

0.1% of Shiseido shares are owned by institutional investors. Comparatively, 3.4% of Takeda Pharmaceutical shares are owned by institutional investors. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Shiseido and Takeda Pharmaceutical, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Shiseido22202.00
Takeda Pharmaceutical02002.00

Valuation and Earnings

This table compares Shiseido and Takeda Pharmaceutical's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Shiseido$10.38 billion2.83$676.77 million$1.7242.81
Takeda Pharmaceutical$30.20 billion1.76$407.02 million$1.789.48

Shiseido has higher earnings, but lower revenue than Takeda Pharmaceutical. Takeda Pharmaceutical is trading at a lower price-to-earnings ratio than Shiseido, indicating that it is currently the more affordable of the two stocks.

Dividends

Shiseido pays an annual dividend of $0.27 per share and has a dividend yield of 0.4%. Takeda Pharmaceutical pays an annual dividend of $0.72 per share and has a dividend yield of 4.3%. Shiseido pays out 15.7% of its earnings in the form of a dividend. Takeda Pharmaceutical pays out 40.4% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

Summary

Takeda Pharmaceutical beats Shiseido on 9 of the 13 factors compared between the two stocks.


Shiseido Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
GlaxoSmithKline logo
GSK
GlaxoSmithKline
1.1$38.35+1.1%$103.26 billion$43.10 billion11.80Dividend Increase
CSL logo
CSLLY
CSL
1.0$107.99+0.1%$98.30 billion$9.15 billion46.75Analyst Upgrade
Zoetis logo
ZTS
Zoetis
1.8$171.55+2.3%$81.48 billion$6.26 billion50.91Earnings Announcement
Analyst Report
Analyst Revision
News Coverage
Bayer Aktiengesellschaft logo
BAYRY
Bayer Aktiengesellschaft
1.0$16.47+0.9%$61.44 billion$48.23 billion-6.15Upcoming Earnings
Vertex Pharmaceuticals logo
VRTX
Vertex Pharmaceuticals
2.0$215.01+0.9%$55.66 billion$4.16 billion27.15Analyst Upgrade
Insider Selling
Analyst Revision
Takeda Pharmaceutical logo
TAK
Takeda Pharmaceutical
1.3$16.87+1.5%$53.24 billion$30.20 billion56.24Upcoming Earnings
News Coverage
Regeneron Pharmaceuticals logo
REGN
Regeneron Pharmaceuticals
2.6$496.75+0.4%$53.22 billion$7.86 billion18.16Earnings Announcement
Analyst Report
News Coverage
Alexion Pharmaceuticals logo
ALXN
Alexion Pharmaceuticals
1.7$170.43+0.3%$37.67 billion$4.99 billion39.82Analyst Upgrade
Analyst Revision
Astellas Pharma logo
ALPMY
Astellas Pharma
1.7$15.40+0.8%$28.67 billion$11.97 billion22.32
BeiGene logo
BGNE
BeiGene
1.1$311.97+0.7%$28.61 billion$428.21 million-15.44Earnings Announcement
Insider Selling
Analyst Revision
News Coverage
Gap Up
Takeda Pharmaceutical logo
TKPYY
Takeda Pharmaceutical
1.0$16.87+1.5%$26.36 billion$15.99 billion12.11High Trading Volume
News Coverage
Royalty Pharma logo
RPRX
Royalty Pharma
1.9$40.97+0.2%$24.87 billionN/A0.00Upcoming Earnings
News Coverage
Genmab A/S logo
GMAB
Genmab A/S
1.4$37.40+0.5%$24.53 billion$804.57 million28.99Earnings Announcement
Analyst Revision
News Coverage
Genmab A/S logo
GNMSF
Genmab A/S
0.6$381.17+5.9%$23.51 billion$804.57 million5.41Gap Down
MERCK Kommanditgesellschaft auf Aktien logo
MKGAF
MERCK Kommanditgesellschaft auf Aktien
0.5$174.00+4.7%$22.49 billion$18.09 billion0.00Upcoming Earnings
Horizon Therapeutics Public logo
HZNP
Horizon Therapeutics Public
2.8$87.93+2.2%$19.70 billion$1.30 billion24.02Earnings Announcement
Gap Up
UCB logo
UCBJF
UCB
1.0$98.00+0.0%$19.06 billion$5.50 billion16.84
CureVac logo
CVAC
CureVac
0.7$100.40+6.4%$18.77 billionN/A0.00Increase in Short Interest
Gap Up
Catalent logo
CTLT
Catalent
1.7$107.56+1.3%$18.32 billion$3.09 billion68.51Earnings Announcement
Analyst Upgrade
News Coverage
Elanco Animal Health logo
ELAN
Elanco Animal Health
1.4$32.88+5.6%$15.55 billion$3.07 billion-57.68Earnings Announcement
News Coverage
Alnylam Pharmaceuticals logo
ALNY
Alnylam Pharmaceuticals
2.0$131.30+0.6%$15.43 billion$219.75 million-16.77Analyst Report
BioMarin Pharmaceutical logo
BMRN
BioMarin Pharmaceutical
2.1$77.77+1.1%$14.21 billion$1.70 billion17.80Insider Selling
Zai Lab logo
ZLAB
Zai Lab
1.6$158.14+1.6%$14.10 billion$12.98 million-52.19Upcoming Earnings
Insider Selling
OPHLF
Ono Pharmaceutical
1.1$25.90+3.3%$13.32 billion$2.69 billion23.55Upcoming Earnings
Grifols logo
GRFS
Grifols
1.3$18.23+1.4%$12.53 billion$5.71 billion16.28Earnings Announcement
Dr. Reddy's Laboratories logo
RDY
Dr. Reddy's Laboratories
1.3$71.02+0.5%$11.81 billion$2.32 billion58.69
Teva Pharmaceutical Industries logo
TEVA
Teva Pharmaceutical Industries
1.6$10.40+1.1%$11.36 billion$16.89 billion-2.83Analyst Downgrade
Bausch Health Companies logo
BHC
Bausch Health Companies
1.9$28.08+1.1%$10.06 billion$8.60 billion-5.15Earnings Announcement
Analyst Report
Analyst Revision
Jazz Pharmaceuticals logo
JAZZ
Jazz Pharmaceuticals
2.1$174.59+1.0%$9.93 billion$2.16 billion55.08Earnings Announcement
Analyst Report
Insider Selling
News Coverage
Maravai LifeSciences logo
MRVI
Maravai LifeSciences
1.6$37.15+4.2%$9.57 billionN/A0.00Upcoming Earnings
Analyst Downgrade
Decrease in Short Interest
Gap Down
United Therapeutics logo
UTHR
United Therapeutics
1.7$195.42+1.7%$8.75 billion$1.45 billion18.49Earnings Announcement
Analyst Report
News Coverage
Ultragenyx Pharmaceutical logo
RARE
Ultragenyx Pharmaceutical
1.7$114.53+1.0%$7.73 billion$103.71 million-26.09Earnings Announcement
Analyst Upgrade
Insider Selling
Analyst Revision
News Coverage
Mirati Therapeutics logo
MRTX
Mirati Therapeutics
1.6$144.00+4.7%$7.39 billion$3.34 million-18.70Earnings Announcement
News Coverage
Gap Up
BridgeBio Pharma logo
BBIO
BridgeBio Pharma
2.0$48.03+3.2%$7.17 billion$40.56 million-14.09Earnings Announcement
Analyst Report
News Coverage
Gap Up
Ascendis Pharma A/S logo
ASND
Ascendis Pharma A/S
1.5$132.90+0.0%$7.14 billion$14.98 million-16.19Analyst Revision
News Coverage
Arrowhead Pharmaceuticals logo
ARWR
Arrowhead Pharmaceuticals
1.5$66.38+1.1%$6.91 billion$87.99 million-79.02Earnings Announcement
Analyst Revision
News Coverage
GW Pharmaceuticals logo
GWPH
GW Pharmaceuticals
1.3$218.96+0.0%$6.86 billion$311.33 million-127.30Earnings Announcement
Analyst Downgrade
Evotec logo
EVTCY
Evotec
0.5$81.29+2.3%$6.69 billion$500.07 million451.64Upcoming Earnings
Sarepta Therapeutics logo
SRPT
Sarepta Therapeutics
1.9$74.57+0.1%$5.95 billion$380.83 million-9.54Earnings Announcement
Perrigo logo
PRGO
Perrigo
2.2$42.96+0.7%$5.74 billion$4.84 billion-715.88Upcoming Earnings
TG Therapeutics logo
TGTX
TG Therapeutics
1.8$40.20+0.9%$5.69 billion$150,000.00-18.96Upcoming Earnings
Analyst Revision
Blueprint Medicines logo
BPMC
Blueprint Medicines
1.5$94.93+1.8%$5.54 billion$66.51 million17.51Analyst Report
News Coverage
Allakos logo
ALLK
Allakos
1.7$100.93+1.8%$5.40 billionN/A-36.84Upcoming Earnings
Analyst Revision
News Coverage
Ionis Pharmaceuticals logo
IONS
Ionis Pharmaceuticals
1.6$36.54+2.2%$5.15 billion$1.12 billion76.13Earnings Announcement
Analyst Report
High Trading Volume
News Coverage
Gap Up
Galapagos logo
GLPG
Galapagos
1.3$75.04+1.5%$4.92 billion$1.00 billion-11.37News Coverage
Gap Up
Schrödinger logo
SDGR
Schrödinger
1.6$68.37+1.7%$4.79 billion$85.54 million0.00Upcoming Earnings
Analyst Downgrade
Insider Selling
Biohaven Pharmaceutical logo
BHVN
Biohaven Pharmaceutical
1.8$71.44+0.9%$4.43 billionN/A-5.82Upcoming Earnings
Analyst Revision
Sage Therapeutics logo
SAGE
Sage Therapeutics
1.4$75.07+4.0%$4.39 billion$6.87 million-7.25Earnings Announcement
Analyst Report
Analyst Revision
News Coverage
Gap Down
I-Mab logo
IMAB
I-Mab
1.2$59.28+0.5%$4.27 billion$4.31 million-2.05Analyst Revision
Hypera logo
HYPMY
Hypera
0.9$6.54+0.3%$4.14 billion$834.89 million15.21
This page was last updated on 5/9/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.